Black checkmark with a sparkle and a curved line underneath on a white background.
Company

BeyondSpring Inc.

Ticker
BYSI
Sector
Industry
Report date
November 17, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight BeyondSpring's financial gains from a subsidiary sale, clinical progress with Plinabulin including FDA Fast Track designation, and improved cash position.

Recent developments:
  • BeyondSpring reported a $50 million profit in Q3 2026 from the sale of a subsidiary and announced plans for a Phase 3 clinical trial of DUBLIN-4 in China [N1].
  • The company received FDA Fast Track designation for Plinabulin in lung cancer, supporting its regulatory pathway [N3].
  • Cash position improved notably in fiscal Q2 2025, reflecting enhanced liquidity [N2].
  • Promising clinical results were reported for Plinabulin in combination therapy for patients refractory to immune checkpoint inhibitors and in metastatic cancer, including Phase 2 interim data showing median progression-free survival of 6.8 months and 78% overall survival rate [N3,N4,N6].
  • BeyondSpring's full-year loss declined as of early 2025, indicating improving financial performance [N5].
  • The company announced a $35.4 million sale of Series A-1 preferred shares in SEED Therapeutics, reflecting strategic investment activity [N4].
Overview

BeyondSpring Inc. operates in the biopharmaceutical sector, developing novel therapies with a focus on oncology. Its lead drug candidate, Plinabulin, is undergoing clinical trials for treatment of lung cancer and metastatic cancers. The company has a subsidiary, Wanchunbulin, operating under a government grant agreement in China with specific operational restrictions. BeyondSpring maintains leased office facilities in New Jersey and China. The company has reported positive clinical trial results and has engaged in strategic transactions including the sale of a subsidiary and investment in SEED Therapeutics. Financially, BeyondSpring reported net income in Q3 2026, supported by non-operating gains, but liquidity ratios indicate tight short-term financial flexibility.

Executive summary

BeyondSpring Inc. is a biopharmaceutical company focused on drug development, notably its lead candidate Plinabulin. The company reported a net income of $50.792 million for Q3 2026, driven by a $50 million profit from the sale of a subsidiary. It has ongoing clinical development programs including a planned Phase 3 trial in China and has received FDA Fast Track designation for Plinabulin in lung cancer. Financial disclosures indicate limited liquidity with a current ratio of 0.28 as of September 30, 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for BYSI

Bull case model:

BeyondSpring has demonstrated clinical progress with Plinabulin, including promising Phase 2 data and plans for Phase 3 trials in China. The FDA Fast Track designation for lung cancer treatment highlights regulatory recognition of its potential. The company's ability to generate a $50 million profit from a subsidiary sale and improve its financial results suggests operational execution capabilities. Strategic investments and partnerships may enhance its development pipeline and market reach.

Bear case model:

BeyondSpring faces liquidity constraints as indicated by a current ratio of 0.28 and cash ratio of 0.13 as of September 30, 2026, which may limit operational flexibility. The company relies heavily on clinical trial success and regulatory approvals, which carry inherent risks and uncertainties. Restrictions from government grant agreements may limit expansion opportunities in China. The biopharmaceutical sector's competitive landscape and high R&D costs pose ongoing risks to sustained profitability and growth.

Moat:

BeyondSpring's moat is primarily based on its proprietary drug development pipeline, particularly Plinabulin, which has received FDA Fast Track designation and demonstrated promising clinical results. The company's strategic partnerships and government grant agreements in China provide localized operational advantages. However, the biopharmaceutical industry is highly competitive and dependent on successful clinical development and regulatory approvals, which pose ongoing challenges to sustaining competitive advantage.

Risks overview
Risks summary
Liquidity constraints combined with clinical and regulatory uncertainties represent the primary risks to BeyondSpring's operational and financial stability.
Risks details:

• Liquidity Risk: The company's current ratio of 0.28 and cash ratio of 0.13 as of September 30, 2026, indicate limited short-term liquidity, which may constrain its ability to fund operations and development activities [S2].
• Clinical and Regulatory Risk: BeyondSpring's business depends on successful clinical trials and regulatory approvals for Plinabulin and other candidates. Failure to achieve positive trial outcomes or regulatory setbacks could materially impact the company.
• Operational Restrictions in China: The subsidiary Wanchunbulin is subject to a government grant agreement that restricts its ability to expand research and commercialization activities outside designated districts until 2033, potentially limiting growth opportunities [S1].
• Dependence on Key Assets and Partnerships: The company’s financial performance and pipeline progress are influenced by strategic transactions such as subsidiary sales and investments in related entities like SEED Therapeutics, which carry execution risks.

FINAL FORECAST FOR BYSI

Final take one line
BeyondSpring Inc. exhibits very high visibility with detailed clinical progress, financial results, and strategic developments supported by comprehensive SEC disclosures.
Final take 12 to 24 month view

Business trends: Clinical advancement of Plinabulin with regulatory designations and strategic asset sales enhancing financial position.
Execution milestones: Completion of Phase 3 trial initiation in China and continued clinical data releases.
Key risks: Liquidity constraints, clinical and regulatory uncertainties, and operational restrictions in China impacting growth potential.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • BeyondSpring Inc. is a biopharmaceutical company engaged in drug development, including clinical trials for its lead candidate Plinabulin.
  • The company has a subsidiary, Wanchunbulin, which has a government grant agreement in China with commitments until 2033 regarding tax jurisdictions and registered capital, limiting expansion within Greater China for related activities [S1].
  • BeyondSpring leases office space in New Jersey and China, with leases expiring in 2027 and 2027 respectively [S1].
  • The company reported a net income of $50.792 million for the quarter ended September 30, 2026, with basic EPS of $1.24 [S2].
  • Cash and cash equivalents were $580,000 as of September 30, 2026, with current assets of $1.284 million and current liabilities of $4.617 million, resulting in a current ratio of 0.28 and a cash ratio of 0.13 [S2].
  • BeyondSpring reported a $50 million profit in Q3 2026 related to the sale of a subsidiary and announced plans for a Phase 3 clinical trial of DUBLIN-4 in China [N1].
  • The company received FDA Fast Track designation for Plinabulin in lung cancer [N3].
  • Promising clinical results have been reported for Plinabulin in combination therapy for patients refractory to immune checkpoint inhibitors and in metastatic cancer, including Phase 2 interim data showing median progression-free survival of 6.8 months and 78% overall survival rate [N3,N4,N6].
  • BeyondSpring's full-year loss declined as of early 2025, indicating improving financial performance [N5].
  • The company announced a $35.4 million sale of Series A-1 preferred shares in SEED Therapeutics, a related entity, reflecting strategic investment activity [N4].
  • Baird maintained an Outperform recommendation on BeyondSpring as of May 2023, reflecting positive market analyst sentiment [N7].
  • The company accrues research contract costs based on progress and milestones in clinical studies, with significant judgment involved in estimating these accruals [S1].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-25 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-16 | www.nasdaq.com | BeyondSpring Turns $50 Mln Profit In Q3 On Sale Of Subsidiary, Plans Phase 3 DUBLIN-4 In China | https://www.nasdaq.com/articles/beyondspring-turns-50-mln-profit-q3-sale-subsidiary-plans-phase-3-dublin-4-china
  • N2 | 2025-08-13 | www.nasdaq.com | BeyondSpring Cash Jumps in Fiscal Q2 | https://www.nasdaq.com/articles/beyondspring-cash-jumps-fiscal-q2
  • N3 | 2025-07-07 | www.nasdaq.com | BeyondSpring Inc. Reports Promising Results of Plinabulin Combination Therapy in Patients Refractory to Immune Checkpoint Inhibitors | https://www.nasdaq.com/articles/beyondspring-inc-reports-promising-results-plinabulin-combination-therapy-patients
  • N4 | 2025-05-12 | www.nasdaq.com | BeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress | https://www.nasdaq.com/articles/beyondspring-inc-reports-positive-early-results-plinabulin-metastatic-cancer-and-updates
  • N5 | 2025-03-27 | www.nasdaq.com | BeyondSpring Inc. Full Year Loss Declines | https://www.nasdaq.com/articles/beyondspring-inc-full-year-loss-declines
  • N6 | 2024-11-11 | www.nasdaq.com | BeyondSpring presents efficacy results from Phase 2 IIT study of plinabulin | https://www.nasdaq.com/articles/beyondspring-presents-efficacy-results-phase-2-iit-study-plinabulin
  • N7 | 2023-05-02 | www.nasdaq.com | Baird Maintains BeyondSpring (BYSI) Outperform Recommendation | https://www.nasdaq.com/articles/baird-maintains-beyondspring-bysi-outperform-recommendation
  • N8 | 2022-08-15 | www.nasdaq.com | Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/clene-inc.-clnn-reports-q2-loss-lags-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine